Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
Yip W, Sjoberg DD, Nogueira LM, Tracey AT, Alvim RG, Reisz PA, Demac Q, Benfante NE, Vanden Berg RW, Kim K, Al-Ahmadie H, Lin O, Bochner BH, Dalbagni G, Donat SM, Pietzak EJ, Hakimi AA, Solit DB, Scherz A, Bajorin DF, Coleman JA. Yip W, et al. Among authors: scherz a. J Urol. 2023 May;209(5):863-871. doi: 10.1097/JU.0000000000003202. Epub 2023 Feb 1. J Urol. 2023. PMID: 36724067 Free PMC article. Clinical Trial.
Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness.
Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, Scardino PT; PCM301 Study Group. Gill IS, et al. Among authors: scherz a. J Urol. 2018 Oct;200(4):786-793. doi: 10.1016/j.juro.2018.05.121. Epub 2018 Jun 2. J Urol. 2018. PMID: 29864437 Free PMC article. Clinical Trial.
Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma.
Corradi RB, LaRosa S, Jebiwott S, Murray KS, Rosenzweig B, Somma AJ, Gomez RS, Scherz A, Kim K, Coleman JA. Corradi RB, et al. Among authors: scherz a. Int J Urol. 2019 Mar;26(3):414-422. doi: 10.1111/iju.13878. Epub 2019 Jan 18. Int J Urol. 2019. PMID: 30659668 Free PMC article.
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Alvim R, Nagar K, Das S, Lebdai S, Wong N, Somma A, Hughes C, Thomas J, Monette S, Scherz A, Kim K, Grimm J, Coleman JA. Alvim R, et al. Among authors: scherz a. Eur Urol Focus. 2021 Mar;7(2):472-478. doi: 10.1016/j.euf.2019.06.008. Epub 2019 Jun 18. Eur Urol Focus. 2021. PMID: 31227464 Free PMC article.
Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
Alvim RG, Georgala P, Nogueira L, Somma AJ, Nagar K, Thomas J, Alvim L, Riegel A, Hughes C, Chen J, Reis AB, Lebdai S, Scherz A, Zanganeh S, Gardner R, Kim K, Coleman JA. Alvim RG, et al. Among authors: scherz a. Molecules. 2021 Jun 19;26(12):3744. doi: 10.3390/molecules26123744. Molecules. 2021. PMID: 34205347 Free PMC article.
169 results